Key clinical point: The 2-year follow-up results of the phase 3 DISCOVER 2 study revealed the robust and sustained efficacy of 100 mg guselkumab every 4 weeks (Q4W) and 100 mg guselkumab every 8 weeks (Q8W) in improving signs and symptoms of psoriatic arthritis (PsA) in biologic-naive patients along with a consistent safety profile.
Major finding: At week 100, at least 20% improvement in American College of Rheumatology criteria was achieved by 76%, 74%, and 68% of patients who received guselkumab Q4W, guselkumab Q8W, and placebo, respectively, indicating a durable response . No new safety signals were identified.
Study details: Findings are from the phase 3 DISCOVER 2 study including 739 biologic-naive patients with active PsA, who were randomly assigned to 100 mg guselkumab Q4W, 100 mg guselkumab Q8W, or placebo. A total of 652 patients completed treatment through week 100.
Disclosures: This study was funded by Janssen Research & Development, LLC, a Johnson & Johnson company. Six authors declared being employees and stockholders of Johnson & Johnson , and the others reported ties with several sources, including Janssen.
Source: McInnes IB et al. Arthritis Rheumatol. 2021(Nov 1). Doi: 10.1002/art.42010.